Open access
Open access
Powered by Google Translator Translator

#ESMO19 – [Abstract Only] Randomized Trial: Improved Overall Survival at 5 Years with Combined Immunotherapy for Advanced Melanoma

30 Sep, 2019 | 00:37h | UTC

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma – New England Journal of Medicine (link to abstract – $ for full-text)

Commentaries: Skin cancer: Half of people surviving advanced melanoma – BBC (free) AND Combination immunotherapy drugs herald new hope for melanoma patients with long term survival rates – The Royal Marsden NHS Foundation Trust (free)

#ESMO19 – Just presented at the European Society of Medical Oncology Congress 2019 in Barcelona

 

Related Commentary on Twitter

 


Stay Updated in Your Specialty

No spam, just news.